▶주메뉴 바로가기
▶본문 바로가기
New drug developer Voronoi is seeking to raise fresh funds worth 100 billion won (US$89 million) ahead of a potential initial public offering, according to news reports on Feb. 8. Established in 201...
Daewoong Pharmaceutical Chairman Jeon Seung-ho on Feb. 1 strongly refuted allegations by its rivals that it stole manufacturing secrets to develop botulinum toxin Nabota. The announcement came after...
[THE INVESTOR] Korean drug maker KyungDong Pharmaceutical said on Feb. 1 that it has invested 1 billion won (US$894,694) in a biotech and health care related startup focused fund led by venture capi...
[THE INVESTOR] Korean 3D bio-printer maker Rokit has secured 11 billion won (US$9.89 million) in funding from KB Investment, Korea Development Bank and DAYLI Partners, according to sources on Jan.31...
[THE INVESTOR] Korean pharmaceutical firm Samsung Bioepis saw its accumulated sales in the European market hit US$545.2 million last year, data showed on Jan. 30. Sales of three biosimilar produ...
[THE INVESTOR] Genosco, a US-based subsidiary of Korean bio company Oscotec, is gearing up to go public, according to industry sources on Jan. 28. The company recently sent out a request for propos...
[THE INVESTOR] LG Household & Health Care said on Jan. 24 its net profit jumped 12 percent on-year fueled by the popularity of its luxury cosmetics brands. Its net profit came to 692 billion won...
[THE INVESTOR] Korean firm Bio Leaders announced on Jan. 23 that it will set up a biotech incubating entity in Israel with venture capital firm Yozma Group. “The official contract to establish the ...
[THE INVESTOR] Hanmi Pharmaceutical said on Jan. 23 that its partner Eli Lilly would hand back its licensed new drug candidate BTK inhibitor in rheumatoid arthritis and its commercialization rights....
[THE INVESTOR] Exports of drug-manufacturing technologies by Korean pharmaceutical and bio companies reached nearly 5.3 trillion won (US$4.70 billion) in 2018, government data showed on Jan. 22. ...
[THE INVESTOR] A Seoul court approved on Jan. 22 a request by Samsung BioLogics to put on hold the execution of penalties by the financial watchdog for the company’s suspected accounting irregularit...
[THE INVESTOR] Samsung Bioepis’ Ontruzant, a breast cancer treatment biosimilar referencing Roche’s Herceptin, won US Food and Drug Administration approval on Jan. 19, expanding the list of Hercepti...
[ THE INVESTOR] Korea’s leading biosimilar firm Celltrion announced on Jan. 18 that it has won a lawsuit over invalidating Samsung Biogen’s patent on Rituxan, a blockbuster drug for treating non-Ho...
[THE INVESTOR] Korea’s largest biopharmaceutical business association announced on Jan. 17 that it aims to boost the local industry in 2019 and make it a global powerhouse. “This year, we must use ...
[THE INVESTOR] Bukwang Pharmaceutical announced on Jan. 15 that is has sold its 7.11 percent stake, worth around 39.7 billion won (US$35.40 million), in Anterogen through an after-hours block deal. ...
Rents, commissions lowered as virus rages through economy
Hanjin Group to sell hotel assets for financial health
Mobility startups immune to coronavirus outbreak
Baedal Minjok to financially support riders during coronavirus emergency
Amorepacific to sell Gangnam building for W160b
Delta hikes stake in Hanjin KAL in support of chairman
JR AMC gets green light for Korea’s 1st cross-border REIT listing
Meet the ‘3 Bs’ behind South Korea’s soft power
February 27, 2020
